Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Gilead Sciences, Inc.

NASDAQ: GILD · Life Sciences · 12 alerts · CIK 882095

Share price
$167.58Close, Nov 16
Market cap
$208B
Shares outstanding
1.24BLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Gilead Sciences, Inc. filings on SEC EDGAR ↗

6:09 AM ET 10-Q
Financial Results ▶ Call

Gilead Sciences Q3 2026 Results: Net Income $2.43B, Down 20.4% YoY

Gilead Sciences reported total revenues of $8.3 billion for the third quarter of 2026, driven by $8.29 billion in product sales. Despite a profitable third quarter, the company recorded a net loss of $6.05 billion for the first nine months of 2026, primarily due to $11.3 billion in acquired in-process research and development expenses.

Key figure
Net income $2.43B · -20.4% YoY
4:05 PM ET 8-K
Financial Results

Gilead Sciences Financial Results

Gilead Sciences reported third-quarter 2026 financial results, featuring a 13% increase in total product sales to $8.3 billion, driven by strong performance in its HIV portfolio. The company raised its full-year base business revenue guidance for the second time this year, citing robust demand for Biktarvy and HIV prevention products.

“Gilead delivered an exceptional third quarter, with our strongest year-over-year base business growth in more than a decade, reflecting the strength, breadth and durability of our business.”

Daniel O’Day, Gilead’s Chairman and Chief Executive Officer

“Our performance enabled us to raise our full year base business revenue guidance again this quarter, bringing the total increase to $1.6 billion since the start of 2026.”

Daniel O’Day, Gilead’s Chairman and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.